DF 5300
Alternative Names: DF-5300Latest Information Update: 03 Aug 2022
At a glance
- Originator Dragonfly Therapeutics
- Class Immunotherapies
- Mechanism of Action Immunostimulants; Natural killer cell stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Autoimmune disorders; Fibrosis
Most Recent Events
- 12 Jul 2022 Preclinical trials in Autoimmune disorders in USA (Parenteral) before July 2022 (Dragonfly Therapeutics pipeline, July 2022)
- 12 Jul 2022 Preclinical trials in Fibrosis in USA (Parenteral) (Dragonfly Therapeutics pipeline, July 2022)
- 12 Jan 2021 NK cell engager based immunotherapeutics licensed to AbbVie worldwide for the treatment of Autoimmune disorders and Fibrotic diseases